(vianews) - shares of poxel (cac 40: poxel.pa) slid by a staggering 27.98% in 21 sessions from €0.97 to €0.70 at 16:07 est on wednesday, after five successive sessions in a row of losses. cac 40 is jumping 0.19% to €7,281.71, after three consecutive sessions in a row of losses.
poxel's last close was €0.68, 79.38% under its 52-week high of €3.28.
about poxel
poxel s.a., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. the company's lead product is twymeeg (imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in japan. it also develops pxl770, an adenosine monophosphate-activated protein kinase enzyme, which is in a phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (nash). poxel s.a. has a licensing agreement with enyo pharma s.a.s. for the development of farnesoid x receptor that is in phase 2a study for the treatment of hepatitis b and nash; and deuterx llc for the development of pxl065, a mitochondrial pyruvate carrier inhibitor, which is in a phase i clinical trial for the treatment of nash. the company was incorporated in 2009 and is headquartered in lyon, france.
earnings per share
as for profitability, poxel has a trailing twelve months eps of €-0.92.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -323.36%.yearly top and bottom value
poxel's stock is valued at €0.70 at 16:07 est, way below its 52-week high of €3.28 and higher than its 52-week low of €0.67.
moving average
poxel's worth is way below its 50-day moving average of €0.95 and way below its 200-day moving average of €1.54.volatility
poxel's last week, last month's, and last quarter's current intraday variation average was a negative 5.97%, a negative 2.10%, and a positive 2.47%.
poxel's highest amplitude of average volatility was 5.97% (last week), 2.72% (last month), and 2.47% (last quarter).
revenue growth
year-on-year quarterly revenue growth declined by 99.4%, now sitting on 206k for the twelve trailing months.
more news about poxel (poxel.pa).
